Future cardiology最新文献

Current opinions on the role of apolipoprotein B in the clinical management of cardiovascular risk. 载脂蛋白B在心血管危险临床管理中的作用

IF 1.6

Future cardiology Pub Date : 2025-07-16 DOI: 10.1080/14796678.2025.2535184

Rafael Zubiran, Alan T Remaley

引用次数: 0

Contemporary antiarrhythmic pharmacotherapy: revisiting the Old, exploring the New. 当代抗心律失常药物治疗：重访旧，探索新。

IF 1.6

Future cardiology Pub Date : 2025-07-15 DOI: 10.1080/14796678.2025.2534323

Stefan Totolici, Raluca Popescu, G-Andrei Dan

引用次数: 0

Recent developments in systemic light-chain amyloidosis prognosis and treatment. 系统性轻链淀粉样变预后及治疗的最新进展。

IF 1.6

Future cardiology Pub Date : 2025-07-12 DOI: 10.1080/14796678.2025.2529701

Adam Ioannou

{"title":"Recent developments in systemic light-chain amyloidosis prognosis and treatment.","authors":"Adam Ioannou","doi":"10.1080/14796678.2025.2529701","DOIUrl":"https://doi.org/10.1080/14796678.2025.2529701","url":null,"abstract":"Systemic light-chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the production of abnormal immunoglobulin free light-chains that misfold into amyloid fibrils and deposit in the extracellular matrix of tissues. Despite being a multisystemic disease process, the presence and severity of cardiac involvement remains the main determinant of prognosis. Improved understanding of the underlying pathophysiology has resulted in transformative changes in both diagnostics and treatment. Improvements in multimodality cardiac imaging have enabled accurate diagnosis, facilitated rapid initiation of treatment and allowed the direct visualization changes in the myocardial substrate in response to chemotherapy. Significant progress has also been made through leveraging treatments that directly target the underlying abnormal plasma cell clone responsible the production of the amyloidogenic immunoglobulin free light-chains. Current treatment options successfully target amyloid production, but novel anti-amyloid therapies seek to target amyloid fibrils that have already deposited in the organs and facilitate their removal through an immune-mediated degradation process are at advanced stages of development. These treatments have the potential to induce disease regression by depleting amyloid deposits and if successful will represent a significant step forward in the treatment of systemic AL amyloidosis, especially for patients with advanced cardiac disease.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-13"},"PeriodicalIF":1.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current landscape for connective tissue disease associated-pulmonary arterial hypertension: a focus on right ventricular adaptation and failure. 结缔组织疾病相关肺动脉高压的现状：关注右心室适应和衰竭

IF 1.6

Future cardiology Pub Date : 2025-07-11 DOI: 10.1080/14796678.2025.2529696

Qianwen Wu, Huangshu Ye, Zhangdi Zhou, Miaojia Zhang, Xiaoxuan Sun, Qiang Wang

{"title":"Current landscape for connective tissue disease associated-pulmonary arterial hypertension: a focus on right ventricular adaptation and failure.","authors":"Qianwen Wu, Huangshu Ye, Zhangdi Zhou, Miaojia Zhang, Xiaoxuan Sun, Qiang Wang","doi":"10.1080/14796678.2025.2529696","DOIUrl":"https://doi.org/10.1080/14796678.2025.2529696","url":null,"abstract":"Right ventricular (RV) function is the primary determinant of survival in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). A \"double hit\" hypothesis suggests that RV suffers not only from pressure overload common to all PAH but also from direct insults related to the underlying systemic autoimmunity and inflammation. This likely drives distinct maladaptive remodeling (fibrosis, inflammation) and contributes to the poorer prognosis observed in CTD-PAH compared to idiopathic PAH (IPAH).Comprehensive, multi-modal RV assessment - integrating clinical evaluation, biomarkers, echocardiography, cardiac MRI, and right heart catheterization - is crucial for prognosis and monitoring therapy. RV size, function, and tissue characteristics are key indicators.Current management involves PAH-targeted therapies to reduce RV afterload, optimal CTD control, and supportive care. However, CTD-PAH often shows attenuated treatment responses and worse outcomes, emphasizing the need for therapies directly addressing RV maladaptation. Future research priorities include understanding specific RV injury mechanisms in CTD, refining assessment tools, and developing novel RV-directed strategies. Optimizing outcomes requires a deep understanding of RV pathobiology within the CTD context and integrated, multidisciplinary care.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Qualitative analysis of experiences, burdens, and needs among patients with hypertrophic cardiomyopathy in Japan. 日本肥厚性心肌病患者的经历、负担和需求的定性分析。

IF 1.6

Future cardiology Pub Date : 2025-07-11 DOI: 10.1080/14796678.2025.2526279

Yuichiro Maekawa, Yuika Ikeda, Makio Torigoe, Kanako Shimoura, Shintaro Suo, Ryohei Takeda, Hiroaki Kitaoka

{"title":"Qualitative analysis of experiences, burdens, and needs among patients with hypertrophic cardiomyopathy in Japan.","authors":"Yuichiro Maekawa, Yuika Ikeda, Makio Torigoe, Kanako Shimoura, Shintaro Suo, Ryohei Takeda, Hiroaki Kitaoka","doi":"10.1080/14796678.2025.2526279","DOIUrl":"https://doi.org/10.1080/14796678.2025.2526279","url":null,"abstract":"Aim: To identify factors affecting the health-related quality of life (HR-QOL) of symptomatic patients with hypertrophic cardiomyopathy (HCM) using qualitative interviews exploring patients' experiences and perceptions.Patients & methods: This cross-sectional observational study was conducted using qualitative web-based or telephone interviews. Adult patients with HCM in Japan who were experiencing burden because of HCM were included. In-depth interviews were conducted using a semi-structured interview guide. The data were analyzed using a thematic analysis approach.Results: Nineteen patients completed the interview. Ten HR-QOL-related themes were identified. Many patients were unaware that they had HCM symptoms, either no longer noticing them following life adjustments or attributing them to factors other than HCM. HCM affected multiple life aspects, including work, family, and social life. Patients resisted disclosing their disease to others and strongly resisted invasive treatment. Patients highly trusted their physicians but were reluctant to discuss their mental burdens and daily life challenges with them.Conclusions: This first qualitative study of HR-QOL in patients with HCM in Japan suggests that deeper physician - patient communication is needed to understand patient burden and needs, as patients have difficulty discussing their burdens with physicians and may lack awareness of HCM symptoms.Clinical trial registration: NCT06181617 (ClinicalTrials.gov).","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-10"},"PeriodicalIF":1.6,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary evidence of non-steroidal mineralocorticoid receptor antagonists in cardio-kidney-metabolic syndrome. 心肾代谢综合征中非甾体矿皮质激素受体拮抗剂的当代证据。

IF 1.6

Future cardiology Pub Date : 2025-07-08 DOI: 10.1080/14796678.2025.2530842

Tanawat Attachaipanich, Kotchakorn Kaewboot, Suthinee Attachaipanich

{"title":"Contemporary evidence of non-steroidal mineralocorticoid receptor antagonists in cardio-kidney-metabolic syndrome.","authors":"Tanawat Attachaipanich, Kotchakorn Kaewboot, Suthinee Attachaipanich","doi":"10.1080/14796678.2025.2530842","DOIUrl":"https://doi.org/10.1080/14796678.2025.2530842","url":null,"abstract":"Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interaction between cardiovascular (CV) disease, chronic kidney disease (CKD), and metabolic risk factors. Non-steroidal mineralocorticoid receptor antagonists (ns-MRAs) are an emerging therapy showing promise in improving CKM syndrome outcomes. A recent large randomized trial, the FINEARTS-HF study, demonstrated a 16% reduction in the composite endpoint of worsening heart failure (HF) and CV death in patients with mildly reduced and preserved ejection fraction after a median 32-month follow-up. Additionally, two pivotal randomized studies demonstrated the efficacy of finerenone in CKD with diabetes patients. The FIDELIO-DKD trial showed a reduction in the renal composite outcome, including kidney failure and related death, over 2.6 years. Similarly, the FIGARO-DKD trial demonstrated a reduction in composite CV outcomes, including CV death, myocardial infarction, stroke, or HF hospitalization, after a median follow-up of 3.4 years. Evidence from in vitro and in vivo studies suggests that finerenone attenuates cardiac and kidney injury by reducing fibrosis, apoptotic cell death, oxidative stress, and endothelial dysfunction. Despite these advances, further research is necessary to evaluate the efficacy of ns-MRAs in specific CKM subpopulations, including HF with reduced ejection fraction and CKD without diabetes, to expand their indications and improve outcomes for CKM syndrome patients.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-15"},"PeriodicalIF":1.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SIRT3 as a potential biomarker and therapeutic target for cardiovascular diseases: a meta-analysis of clinical studies. SIRT3作为心血管疾病的潜在生物标志物和治疗靶点：临床研究的荟萃分析

IF 1.6

Future cardiology Pub Date : 2025-07-04 DOI: 10.1080/14796678.2025.2527535

Nikhil Gupta, Vikas Kumar, Abhinav Kanwal

{"title":"SIRT3 as a potential biomarker and therapeutic target for cardiovascular diseases: a meta-analysis of clinical studies.","authors":"Nikhil Gupta, Vikas Kumar, Abhinav Kanwal","doi":"10.1080/14796678.2025.2527535","DOIUrl":"https://doi.org/10.1080/14796678.2025.2527535","url":null,"abstract":"Background: Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, with mitochondrial dysfunction playing a key role in their pathogenesis. SIRT3 (Sirtuin 3), a mitochondrial deacetylase, has emerged as a critical regulator of mitochondrial function and oxidative stress, with evidence linking its reduction to the progression of CVDs. This meta-analysis aimed to evaluate the association between SIRT3 levels and CVDs in order to elucidate its role in CVD pathogenesis and its potential as a biomarker.Methods: A systematic search of MEDLINE and Embase databases was conducted up to August 2024, adhering to PRISMA guidelines. Observational studies evaluating SIRT3 levels in human patients with CVDs as compared to healthy controls were included.Results: 8 studies comprising 397 participants were included in this meta-analysis. Overall, SIRT3 levels were found to be significantly lower in individuals with CVDs compared to healthy controls (SMD: 1.08, 95% CI: 0.495-1.662, p = 0.0032). The reduction in SIRT3 levels was most pronounced in hypertension (SMD: 1.82) and dilated cardiomyopathy (SMD: 1.08).Conclusion: This meta-analysis provides compelling evidence of gsignificantly reduced SIRT3 levels in CVD patients, highlighting its critical role in cardiovascular diseases. These findings underscore the potential of SIRT3 as a biomarker and therapeutic target in CVDs.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-10"},"PeriodicalIF":1.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac MRI: a pivotal tool for the management of cardiomyopathy. 心脏MRI：心肌病治疗的关键工具。

IF 1.6

Future cardiology Pub Date : 2025-07-03 DOI: 10.1080/14796678.2025.2529692

Edoardo Conte, Susanna Landi, Daniele Andreini

引用次数: 0

The emerging role of artificial intelligence in heart failure. 人工智能在心力衰竭中的新作用。

IF 1.6

Future cardiology Pub Date : 2025-07-03 DOI: 10.1080/14796678.2025.2523155

Brett S Bernstein, Sona Streather, Kevin O'Gallagher

引用次数: 0

The challenges in improving myocardial infarction outcomes and the year 2024 in a nutshell. 改善心肌梗死预后的挑战和2024年的概述。